<unk>  is a P2Y12 platelet inhibitor that is FDA approved for the prevention of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor and undergoing percutaneous coronary intervention (PCI).   Common adverse reactions include bleeding.
Cangrelor
Iofendylate
Cetrorelix
Riociguat
Temocapril
Bemiparin
Prasugrel
Guanadrel